Huang Wukui, You Lina, Liu Dengyao, Yang Shufa, Liu Mo, Wang Hailin, Wang Pingju, Baikere Pahaerding, Gu Peng, Abulikemu Abulajiang, Yuan Shaoha, Fan Xiwen
Department of Interventional Radiology, The Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang, People's Republic of China.
J BUON. 2016 Nov-Dec;21(6):1388-1393.
To assess the efficacy and safety of S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma (HCC).
PubMed, the Cochrane Library, EMBASE, and ClinicalTrials.gov were searched using the terms "Hepatocellular Carcinoma" or "HCC" or "Hepatoma" or "Liver cancer" and "S-1" and "Sorafenib" or "Nexavar". Outcomes of main interest included overall survival (OS) and toxicities.
We identified 2 studies of S"1 plus sorafenib from 77 references that included a total of 65 patients. The percentage of male patients ranged from 70.0 to 89.5%. Median age was 59.2 years and ranged from 48.0 to 65.5 years. The percentage of hepatitis B virus ranged from 23.1 to 90.0%. The recommended dose of S-1 and sorafenib was 80 or 64 mg/m/day and 800 mg/day, respectively and treatment was administered orally on days 1-14 and days 1-21, respectively. Median OS were 10.4 and 10.5 months, respectively. The incidence of all-grade toxicities of more than 30% were hand"foot syndrome (HFS) and rash. The incidence of grade 3/4 toxicities more than 5% were thrombocytopenia, elevated AST/ALT and hyperbilirubinemia.
This systematic review suggests that S-1 plus sorafenib showed modest clinical efficacy and tolerable toxicity profile in patients with advanced HCC. The recommended dose of S-1 and sorafenib was 80 or 64 mg/m/day and 800 mg/day, respectively.
评估S-1联合索拉非尼治疗晚期肝细胞癌（HCC）的疗效和安全性。
在PubMed、Cochrane图书馆、EMBASE和ClinicalTrials.gov数据库中检索，检索词为“肝细胞癌”或“HCC”或“肝癌”或“肝癌”以及“S-1”和“索拉非尼”或“多吉美”。主要关注的结果包括总生存期（OS）和毒性。
我们从77篇参考文献中确定了2项关于S-1联合索拉非尼的研究，共纳入65例患者。男性患者比例为70.0%至89.5%。中位年龄为59.2岁，范围在48.0至65.5岁之间。乙肝病毒感染率为23.1%至90.0%。S-1和索拉非尼的推荐剂量分别为80或64mg/m²/天和800mg/天，治疗分别在第1 - 14天和第1 - 21天口服给药。中位总生存期分别为10.4个月和10.5个月。所有级别毒性发生率超过30%的是手足综合征（HFS）和皮疹。3/4级毒性发生率超过5%的是血小板减少、AST/ALT升高和高胆红素血症。
本系统评价表明，S-1联合索拉非尼在晚期HCC患者中显示出适度的临床疗效和可耐受的毒性特征。S-1和索拉非尼的推荐剂量分别为80或64mg/m²/天和800mg/天。
